Annovis Bio, Inc. (ANVS) vs Xilio Therapeutics, Inc. (XLO)

Annovis Bio, Inc. and Xilio Therapeutics, Inc. are both Biotechnology companies. Annovis Bio, Inc. and Xilio Therapeutics, Inc. are of similar size ($59.2M and $56.8M). Annovis Bio, Inc. has the higher net margin (0.00% vs −34.1%) and the higher return on invested capital (0.00% vs 0.00%). Across the 10 metrics below, Xilio Therapeutics, Inc. leads on 6 and Annovis Bio, Inc. on 4.

Valuation

Metric ANVS XLO Biotechnology median
P/E n/m n/m 7.88
P/S n/m 2.74 11.47
P/B n/m 2.43 2.52
Price to free cash flow n/m n/m 21.16
EV/EBITDA n/m n/m 0.74
EV/Sales n/m 0.75 10.73
Earnings yield (136.64%) (16.49%) (28.84%)
Free cash flow yield (88.18%) (34.93%) (23.03%)

Profitability

Metric ANVS XLO Biotechnology median
Gross margin — 100.00% 65.16%
Operating margin 0.00% (48.94%) 0.00%
Net margin 0.00% (34.06%) 0.00%
Free cash flow margin 0.00% (95.59%) 0.00%
Return on equity (703.68%) (55.03%) (57.72%)
Return on assets (227.74%) (15.16%) (49.22%)
Return on invested capital 0.00% 0.00% 0.00%

Growth

Metric ANVS XLO Biotechnology median
Revenue growth (TTM) — 327.25% 5.64%
EPS growth (last fiscal year) 39.39% 72.55% —
Revenue growth, 5-year CAGR — — 8.40%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric ANVS XLO Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 3.47 4.25 4.73
Net debt to EBITDA 0.66 3.40 0.96

Dividend

Metric ANVS XLO Biotechnology median
Dividend yield — — 2.10%
Payout ratio 0.00 0.00 0.00

Size

Metric ANVS XLO Biotechnology median
Market cap 56.76m 59.22m 162.10m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack